An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response

An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for COVID-19, has caused an ongoing worldwide pandemic. Due to the rapid emergence of variants of concern (VOCs), novel vaccines and vaccination strategies are urgently needed. We developed an intranasal vaccine c...

Full description

Bibliographic Details
Main Authors:	Li Chen, Haiwei Zhang, Moxuan Li, Bihao Wu, Zhe Zhang, Rui Gong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Immunology
Subjects:	SARS-CoV-2 intranasal vaccine RBD-Fc mucosal immunity mucosal vaccine
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.1005321/full

Similar Items

Intranasal Immunization with Zika Virus Envelope Domain III-Flagellin Fusion Protein Elicits Systemic and Mucosal Immune Responses and Protection against Subcutaneous and Intravaginal Virus Challenges
by: Chi-Hsun Chen, et al.
Published: (2022-05-01)

Systemic and Mucosal Antibody Responses to Soluble and Nanoparticle-Conjugated Antigens Administered Intranasally
by: Savannah E. Howe, et al.
Published: (2016-10-01)

Intranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2
by: Wei-Chiao Huang, et al.
Published: (2022-09-01)

A novel simian adenovirus-vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens
by: Panli Zhang, et al.
Published: (2023-12-01)

Intranasal Vaccination With Recombinant Antigen-FLIPr Fusion Protein Alone Induces Long-Lasting Systemic Antibody Responses and Broad T Cell Responses
by: Ming-Shu Hsieh, et al.
Published: (2021-10-01)

Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration
by: Arghavan Soleimanizadeh, et al.
Published: (2021-11-01)

Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2
by: Khue G. Nguyen, et al.
Published: (2022-05-01)

Use of PELC/CpG Adjuvant for Intranasal Immunization with Recombinant Hemagglutinin to Develop H7N9 Mucosal Vaccine
by: Ting-Hsuan Chen, et al.
Published: (2020-05-01)

Vaccine Strategies to Elicit Mucosal Immunity
by: Yufeng Song, et al.
Published: (2024-02-01)

Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2
by: Tuksin Jearanaiwitayakul, et al.
Published: (2021-07-01)

Intranasal COVID-19 vaccines: From bench to bed
by: Aqu Alu, et al.
Published: (2022-02-01)

Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection
by: Minami Nagai, et al.
Published: (2021-08-01)

Oral and intranasal vaccines against SARS‐CoV‐2: Current progress, prospects, advantages, and challenges
by: Sanchita Kar, et al.
Published: (2022-04-01)

A micro-sized vaccine based on recombinant Lactiplantibacillus plantarum fights against SARS-CoV-2 infection via intranasal immunization
by: Letian Li, et al.
Published: (2023-07-01)

Polymeric Nanoparticles as Oral and Intranasal Peptide Vaccine Delivery Systems: The Role of Shape and Conjugation
by: Prashamsa Koirala, et al.
Published: (2024-02-01)

COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges
by: Kuldeep Dhama, et al.
Published: (2022-11-01)

Intranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants
by: Michael J. Moser, et al.
Published: (2023-06-01)

Intranasal immunisation with recombinant Toxoplasma gondii uridine phosphorylase confers resistance against acute toxoplasmosis in mice
by: Yin Li-Tian, et al.
Published: (2023-01-01)

Preclinical Efficacy of a Trivalent Human FcγRI-Targeted Adjuvant-Free Subunit Mucosal Vaccine against Pulmonary Pneumococcal Infection
by: Sudeep Kumar, et al.
Published: (2020-04-01)

Intranasal Therapeutic Peptide Vaccine Promotes Efficient Induction and Trafficking of Cytotoxic T Cell Response for the Clearance of HPV Vaginal Tumors
by: Gloria Sierra, et al.
Published: (2020-05-01)

Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives
by: Yingying Xu, et al.
Published: (2014-07-01)

SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
by: Raju Sunagar, et al.
Published: (2023-04-01)

A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice
by: Entao Li, et al.
Published: (2019-08-01)

Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice
by: Tao Hua, et al.
Published: (2022-09-01)

Differential Biodistribution of Adenoviral-Vectored Vaccine Following Intranasal and Endotracheal Deliveries Leads to Different Immune Outcomes
by: Vidthiya Jeyanathan, et al.
Published: (2022-06-01)

Corrigendum: Differential biodistribution of adenoviral-vectored vaccine following intranasal and endotracheal deliveries leads to different immune outcomes
by: Vidthiya Jeyanathan, et al.
Published: (2023-02-01)

Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial
by: Sybil Tasker, et al.
Published: (2021-03-01)

Randomized controlled field trial to assess the efficacy of an intranasal Moraxella bovis cytotoxin vaccine against naturally occurring infectious bovine keratoconjunctivitis
by: John A. Angelos, et al.
Published: (2023-12-01)

Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics
by: Kaori Sano, et al.
Published: (2018-08-01)

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
by: Meera Madhavan, et al.
Published: (2022-11-01)

Current Status of Intranasal COVID-19 Vaccine, its Usage and Efficacy: A Narrative Review
by: Ratan Tandon, et al.
Published: (2023-05-01)

Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs
by: Santosh Dhakal, et al.
Published: (2018-05-01)

Sinonasal Mucosal Melanoma: A Rare Intranasal Tumor in an 89-Year-Old Woman
by: Jeremiah Esguerra
Published: (2023-06-01)

Intranasally Delivered Adenoviral Vector Protects Chickens against Newcastle Disease Virus: Vaccine Manufacturing and Stability Assessments for Liquid and Lyophilized Formulations
by: Omar Farnós, et al.
Published: (2023-12-01)

Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
by: Raju Sunagar, et al.
Published: (2022-12-01)

Evaluation of the Mucosal Immunity Effect of Bovine Viral Diarrhea Virus Subunit Vaccine E2Fc and E2Ft
by: Yanqing Cheng, et al.
Published: (2023-02-01)

Mucosal vaccine delivery: A focus on the breakthrough of specific barriers
by: Mengwen Huang, et al.
Published: (2022-09-01)

Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice
by: Andrea N. Loes, et al.
Published: (2020-09-01)

Intranasal vaccination with extracellular serine proteases of Leishmania amazonensis confers protective immunity to BALB/c mice against infection
by: Herbert Leonel de Matos Guedes, et al.
Published: (2014-09-01)

Immunogenicity of the drug "Live intranasal vaccine for the prevention of pertussis" (GamLPV) with a single use in healthy volunteers
by: A. Yu. Medkova, et al.
Published: (2022-01-01)